A Cluster Controlled Trial Comparing Three Methods of Disseminating Practice Guidelines for Children With Croup
NCT ID: NCT00147849
Last Updated: 2005-11-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
INTERVENTIONAL
2000-09-30
2006-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Intervention Strategies: The intervention strategies to be compared will be mailing of printed educational materials (the "Standard intervention"), mailing plus a combination of interactive educational meetings, educational outreach visits, and reminders (a "Saturn intervention"), and a combination of mailing, interactive sessions, outreach visits, reminders plus identification of local opinion leaders and establishment of local consensus processes (a "Cadillac intervention").
Primary Objective: To determine which of the three intervention strategies are most effective at lowering the rate of hospital days per 1,000 disease episodes. The null hypothesis is that none of the intervention strategies reduce hospital utilization rates from baseline. The alternate hypothesis is that the intervention strategies will have a graded degree of effect on hospitalization rates, with the 'Standard intervention' having minimal to no effect, the 'Saturn intervention' having moderate but significant effect, and the 'Cadillac intervention' having the greatest effect.
Secondary Objective: To determine which of the three dissemination strategies are most effective at increasing the use of therapies of known benefit.
Economic Analysis: To determine which of the three intervention strategies will most effectively reduce total societal costs including all health care costs, costs borne by the family, and costs stemming from the strategies for disseminating guidelines.
Other Objectives: To determine which dissemination strategy will most effectively maintain or improve clinical outcomes and maintain or reduce the family psychosocial burden. Clinical outcomes assessed will include both uncommon severe events such as endotracheal intubation, respiratory arrest, and death, as well as average duration of clinical symptoms. The assessment of family psychosocial burden will include the number of hours of sleep missed by the child, and the stress experienced by the primary caregiver (most commonly the mother).
Study Plan: The study objectives will be achieved through the following:
1. We are completing a baseline survey which a) documents Alberta-wide utilization rates for health care services; b) documents severe adverse outcomes Alberta-wide; c) rank orders Alberta hospitals based on rates of hospitalization; d) documents therapeutic practices in 24 selected Alberta hospitals; and e) documents, through the use of a prospectively administered survey, the psychosocial burden of the disease on families in the same 24 Alberta hospitals.
2. We are developing clinical guidelines that address indications for drug therapy and hospital admission/discharge criteria. Development of these guidelines have included the following: a)convening an expert panel; b) critically reviewing the published literature; c) drafting guidelines which meet standard criteria for developing guidelines; d) obtaining approval of the guidelines by the Canadian Pediatric Society, Canadian Association of Emergency Physicians, and the Alberta Medical Association; and e) publishing the guidelines in journals such as the CMAJ.
3. We have identified 24 Alberta hospitals and will randomize them to one of the three dissemination strategies outlined above.
4. We will complete a follow-up survey which a) documents Alberta-wide severe adverse outcomes and utilization rates; b) documents practice patterns in the same 24 Alberta hospitals surveyed at baseline; and c) documents the psychosocial burden of the disease on families in these same hospitals.
5. We will complete a statistical analysis comparing the three randomized groups of hospitals in terms of the change in health care utilization, change in physician use of effective therapies, and change in the psychosocial burden of the disease on families.
6. We will complete an economic analysis that compares the change in benefits derived from the three types of dissemination strategies with the relative costs (change in health care costs, relative costs associated with the three types of dissemination strategies, and change in costs borne by the family such as lost wages).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
ECT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
mailing of printed educational materials
a combination of interactive educational meetings, educational outreach visits, and reminders
identification of local opinion leaders and establishment of local consensus processes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
0 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David W Johnson, MD
Role: PRINCIPAL_INVESTIGATOR
University of Calgary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIHR App No. 110642
Identifier Type: -
Identifier Source: secondary_id
U Calgary Acct. No. 73-1051
Identifier Type: -
Identifier Source: secondary_id
MCT-63141
Identifier Type: -
Identifier Source: org_study_id